Adalimumab
| Evidence Level: L4 | Predicted Indications: 10 |
Table of Contents
Adalimumab: From Inflammatory Arthritis and Bowel Disease to Rheumatoid Vasculitis
One-Sentence Summary
Adalimumab is a TNF-alpha blocking antibody, originally used for rheumatoid arthritis, Crohn disease, ulcerative colitis, psoriatic arthritis, ankylosing spondylitis, juvenile idiopathic arthritis, hidradenitis suppurativa and non-infectious uveitis. The TxGNN model predicts it may be effective for rheumatoid vasculitis. Support is weak: 1 clinical trial (not testing adalimumab for this condition) and 20 publications, mostly case reports, safety reports and reviews.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Rheumatoid arthritis, Crohn disease, ulcerative colitis, psoriatic arthritis, ankylosing spondylitis, juvenile idiopathic arthritis, hidradenitis suppurativa, non-infectious uveitis (the Singapore licence records list no indication text, so these come from the knowledge-graph indication data) |
| Predicted New Indication | Rheumatoid vasculitis |
| TxGNN Prediction Score | 99.80% |
| Evidence Level | L4 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 17 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the compiled data. Adalimumab is a fully human monoclonal antibody that neutralises TNF-alpha, a central driver of inflammation in rheumatoid arthritis and its extra-articular complications. Its efficacy in rheumatoid arthritis is well established.
Rheumatoid vasculitis is a serious extra-articular complication of rheumatoid arthritis. Because it is plausibly TNF-mediated, there is a biological rationale for the prediction. One case report describes digital vasculitis in a rheumatoid arthritis patient that responded well to adalimumab.
The direction of effect is uncertain, however. Anti-TNF agents, adalimumab included, have been reported to induce vasculitis and autoimmune phenomena, such as leukocytoclastic vasculitis, antiphospholipid syndrome and ANCA-associated nephritis. A large UK registry analysis also examined lupus-like and vasculitis-like events in TNF-inhibitor-treated rheumatoid arthritis patients. Adalimumab could therefore help, have no effect, or worsen vasculitis, and only controlled studies can settle this.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT07138898 | Phase 2 | Recruiting | 80 | Perioperative immunosuppressant management in rheumatology patients having elective shoulder replacement. It does not test adalimumab for vasculitis and gives no efficacy evidence for this indication. |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 31491879 | 2019 | Network meta-analysis (36 RCTs) | Int J Mol Sci | Original and biosimilar TNF inhibitors, adalimumab included, similarly reduce joint destruction in rheumatoid arthritis. This concerns joint damage, not vasculitis. |
| 28123776 | 2017 | Cohort study (BSRBR-RA registry) | RMD Open | Compares drug-specific risk of lupus-like and vasculitis-like events in TNF-inhibitor-treated versus conventional-DMARD-treated rheumatoid arthritis patients. |
| 16979537 | 2006 | Review | Best Pract Res Clin Rheumatol | Safety problems of anti-TNF therapy, including reactivation of tuberculosis. |
| 15742457 | 2005 | Review | J Rheumatol Suppl | Compares the efficacy of TNF inhibitors in rheumatoid arthritis and related arthritides. |
| 25133007 | 2014 | Case report | Case Rep Rheumatol | Digital vasculitis in a rheumatoid arthritis patient that responded well to adalimumab. |
| 30773522 | 2019 | Case report | Intern Med | Acute pulmonary hypertension crisis in rheumatoid vasculitis after adalimumab dose reduction. |
| 23559388 | 2013 | Case report | Clin Rheumatol | Adalimumab-associated antiphospholipid syndrome, with a review of anti-TNF-induced vasculitis. |
| 28719435 | 2018 | Case report | Am J Dermatopathol | Leukocytoclastic vasculitis after starting adalimumab for rheumatoid arthritis. |
| 36418100 | 2023 | Case report | Intern Med | ANCA-associated nephritis during abatacept and adalimumab therapy, attenuated by tocilizumab. |
| 24854356 | 2014 | Cohort study | Ann Rheum Dis | Whether routine ANA testing predicts biologic-DMARD-induced lupus and vasculitis in rheumatoid arthritis. |
Singapore Market Information
There are 17 valid licences, all single-ingredient injectable solutions and none cancelled. The licence records list no approved-indication text. The five below are examples.
| Authorization Number | Product Name | Dosage Form |
|---|---|---|
| SIN15248P | Humira 40mg/0.4ml (pre-filled pen) | Injection, solution |
| SIN15786P | Humira 40mg/0.4ml (pre-filled syringe) | Injection, solution |
| SIN15731P | Amgevita 40 mg/0.8 ml (pre-filled syringe) | Injection, solution |
| SIN16273P | Hyrimoz 40mg/0.8ml (pre-filled pen) | Injection, solution |
| SIN16084P | Idacio 40mg/0.8ml (pre-filled syringe) | Injection, solution |
Safety Considerations
Drug Interactions (100 interactions recorded; examples from the data compiled for this report):
- Major
- Corticosteroids: betamethasone, budesonide, dexamethasone, hydrocortisone, prednisolone, prednisone, triamcinolone (including ophthalmic)
- Deferiprone
- Radiolabelled or antibody-based agents: ibritumomab tiuxetan, iobenguane (I-131), tositumomab, tositumomab (I-131)
- Moderate: metronidazole, tinidazole, rosuvastatin, simvastatin
- Minor: zinc acetate, zinc gluconate, zinc sulfate
Safety signals from the literature relevant to this indication:
- Adalimumab and other anti-TNF agents have been linked to drug-induced vasculitis, lupus-like syndromes, antiphospholipid syndrome and ANCA-associated nephritis.
- Anti-TNF therapy carries a risk of tuberculosis reactivation and other infections.
Please refer to the package insert for warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction score is very high (99.80%), and the TNF-driven biology is plausible. Actual evidence is limited to case reports and observational data, however, and the only registered trial does not test adalimumab for vasculitis. Reports of anti-TNF-induced vasculitis mean the direction of effect is unclear. Adalimumab is already marketed in Singapore with 17 registrations, so access is not the obstacle. The obstacle is the lack of efficacy and safety evidence in this condition.
To proceed, the following is needed:
- Controlled or well-designed observational studies of adalimumab specifically in rheumatoid vasculitis
- A systematic review of cases where anti-TNF therapy helped versus induced vasculitis, to clarify the direction of effect
- Package insert warnings and contraindications from the Singapore regulator (HSA)
- Detailed mechanism of action data
- A clear safety monitoring plan for patients with existing vasculitis or autoimmune manifestations
Note on other predictions: Two other predicted indications, inflammatory spondylopathy and polyarticular juvenile rheumatoid arthritis, have much stronger evidence (L1, several Phase 3 trials). They largely match adalimumab's existing approved uses (ankylosing spondylitis and axial spondyloarthritis, and polyarticular JIA), so they are closer to label alignment than true repurposing.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.